Insider Buying: aTyr Pharma Inc (LIFE) Director Acquires $31,634.26 in Stock
aTyr Pharma Inc (NASDAQ:LIFE) Director Paul Schimmel purchased 42,749 shares of the stock in a transaction on Tuesday, September 4th. The shares were acquired at an average price of $0.74 per share, for a total transaction of $31,634.26. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Paul Schimmel also recently made the following trade(s):
- On Thursday, August 30th, Paul Schimmel purchased 164,411 shares of aTyr Pharma stock. The shares were acquired at an average price of $0.74 per share, for a total transaction of $121,664.14.
Shares of NASDAQ LIFE traded up $0.02 during midday trading on Friday, hitting $0.77. The stock had a trading volume of 268,379 shares, compared to its average volume of 671,799. The company has a market cap of $22.39 million, a PE ratio of -0.41 and a beta of 2.98. aTyr Pharma Inc has a 1 year low of $0.60 and a 1 year high of $6.50. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.96 and a quick ratio of 5.96.
A number of equities analysts have issued reports on the company. Citigroup upgraded aTyr Pharma from a “sell” rating to a “neutral” rating and lowered their price target for the stock from $1.00 to $0.75 in a research report on Thursday, August 16th. BMO Capital Markets lowered their price target on aTyr Pharma from $2.00 to $1.00 and set a “hold” rating on the stock in a research report on Wednesday, August 15th. Zacks Investment Research downgraded aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, July 17th. ValuEngine upgraded aTyr Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $3.00 price target on shares of aTyr Pharma in a research report on Monday, May 14th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company’s stock. aTyr Pharma presently has an average rating of “Hold” and a consensus target price of $1.94.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in LIFE. Deutsche Bank AG purchased a new position in shares of aTyr Pharma in the fourth quarter valued at approximately $199,000. Dimensional Fund Advisors LP lifted its position in shares of aTyr Pharma by 33.5% in the first quarter. Dimensional Fund Advisors LP now owns 114,449 shares of the biotechnology company’s stock valued at $303,000 after acquiring an additional 28,699 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of aTyr Pharma by 37.6% in the second quarter. Renaissance Technologies LLC now owns 533,861 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 145,761 shares in the last quarter. Finally, Sofinnova Ventures Inc purchased a new position in shares of aTyr Pharma in the first quarter valued at approximately $4,945,000. Institutional investors and hedge funds own 44.63% of the company’s stock.
aTyr Pharma Company Profile
aTyr Pharma, Inc, a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings.
Featured Story: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.